Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Combination of pazopanib and paclitaxel safe in urothelial cancer

Prof Sandy Srinivas - Stanford University Medical Centre, Stanford, USA

Combination of pazopanib and paclitaxel safe in urothelial cancer ( Prof Sandy Srinivas - Stanford University Medical Centre, Stanford, USA )

Tackling renal cancer with a combination of autologous immunotherapy and...

Prof Robert Figlin - Cedars-Sinai, Los Angeles, USA

Tackling renal cancer with a combination of autologous immunotherapy and sunitinib ( Prof Robert Figlin - Cedars-Sinai, Los Angeles, USA )

ASCO GU 2015: Prostate highlights from day one

Prof Karim Fizazi, Prof Kurt Miller, Dr Maria De Santis, Dr Mark Rubin

ASCO GU 2015: Prostate highlights from day one ( Prof Karim Fizazi, Prof Kurt Miller, Dr Maria De Santis, Dr Mark Rubin )

Challenging results from mTOR inhibitors in metastatic clear cell renal cancer

Prof Thomas Powles - Barts Health, London, UK

Challenging results from mTOR inhibitors in metastatic clear cell renal cancer ( Prof Thomas Powles - Barts Health, London, UK )

Metastatic prostate cancer - Interpreting negative trial results

Prof Stephane Oudard and Prof Noel Clarke

Metastatic prostate cancer - Interpreting negative trial results ( Prof Stephane Oudard and Prof Noel Clarke )

Efficacy, tolerability and quality of life in metastatic renal cell carcinoma:...

Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France

Efficacy, tolerability and quality of life in metastatic renal cell carcinoma: Welcome and introduction ( Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France )

mRCC: Are we doing all we can to manage adverse events?

Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France

mRCC: Are we doing all we can to manage adverse events? ( Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France )

mRCC: Real-world experience: achieving efficacy beyond clinical trials

Dr Nizar Tannir - University of Texas M.D. Anderson Cancer Center, Houston, USA

mRCC: Real-world experience: achieving efficacy beyond clinical trials ( Dr Nizar Tannir - University of Texas M.D. Anderson Cancer Center, Houston, USA )

mRCC: Understanding the patient's perspective

Dr David Cella - Northwestern University, Chicago, USA

mRCC: Understanding the patient's perspective ( Dr David Cella - Northwestern University, Chicago, USA )

mRCC: Panel discussion

Prof Bernard Escudier, Dr Nizar Tannir, Dr David Cella

mRCC: Panel discussion ( Prof Bernard Escudier, Dr Nizar Tannir, Dr David Cella )

mRCC: Closing remarks

Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France

mRCC: Closing remarks ( Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France )

Optimizing survival in advanced prostate cancer: Understanding PC heterogeneity...

Dr Bertrand Tombal – Saint-Luc Hospital, Brussels, Belgium

Optimizing survival in advanced prostate cancer: Understanding PC heterogeneity to guide treatment choices ( Dr Bertrand Tombal – Saint-Luc Hospital, Brussels, Belgium )

More from ecancer